Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hut 8 Corp (HUT) vs Mesoblast Limited (MESO) Price & Performance

Hut 8 CorpTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Mesoblast Limited — how do they compare? Hut 8 Corp trades at $91.69 (market cap $10.94B), while Mesoblast Limited trades at $16.75 (market cap $2.21B). The key difference: Hut 8 Corp is far larger — about 5× Mesoblast Limited's market cap, and Hut 8 Corp is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

HUTMESO
Market Cap
$10.94B$2.21B
Sector
TechnologyTechnology
52-Week High
$133.02$20.96
52-Week Low
$21.37$12.88
Enterprise Value
$18.38B$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hut 8 Corp

HUT trades at $91.66, up 7.0% today amid a broader neocloud rally following NVIDIA's $500 billion AI pledge. The stock shows a bearish technical trend with support at $87 and resistance at $92. Fundamentally, Q2 2026 revenue grew 81% year-over-year to $74 million, but net losses widened to -$226 million in 2025. The company is transitioning to an AI data center platform, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.

Outlook is polarized: strong analyst buy consensus (94%) targets $165.11, citing AI infrastructure potential, but high execution risks and persistent losses pose threats. Near-term volatility is likely as the market weighs Beacon Point commercialization progress against earnings misses and negative cash flow from operations.

Mesoblast Limited

MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.

MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

Read more on HUT

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO